PBAC's latest decision on Propylene glycol: Recommended with restriction (2024). Considered for Treatment of severe dry eye syndrome. The product provides temporary relief of burning and irritation due to dryness of the eye.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Patients with severe dry eye syndrome requiring ocular lubricant therapy
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Mean change from baseline in tear break-up time (TBUT) at Day 35
Key trials
Jerkin et al 2020 (NCT02776670), Baudouin et al 2012 (NCT00987727)
Comparator
0.1%/0.2% hyaluronate sodium MDPF eye drops (Hylo-Fresh and Hylo-Forte) and 0.5% carmellose sodium + glycerol MDPC eye drops (Optive); lowest cost PBS-listed ocular lubricant for pricing purposes
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC recommended listing on a cost-minimisation basis to the lowest cost PBS-listed ocular lubricant.